INTRODUCTION
Since the discovery of Penicillin in 1928, antibiotics have brought about a revolution in medicine, saving lives of many patients who would have previously died from infections. There is no doubt that antibiotics have proved extremely efficient against a wide range of bacterial species. It is therefore not surprising that antibiotics are the most commonly prescribed medication to infants and children in the Western world (Chai et al. 2012) . In fact, antibiotics are administered to over 10% of European children yearly (Sturkenboom et al. 2008) . In the USA, antibiotics account for 25% of all the prescriptions written to the pediatric population, with the most common types being amoxicillin, azithromycin and amoxicillin/clavulanate (Chai et al. 2012) . However, numerous pieces of evidence have begun to indicate that there may also be a price for such frequent antibiotic use. With the development of microbiome research and recognition of the essential roles of microbiota in overall health, concern has been raised regarding the effects of antibiotics on the healthy microbial components residing within our bodies. It has indeed been shown that antibiotic treatment dramatically alters both adult and infant microbiome compositions (Francino 2015; Azad et al. 2016; Yassour et al. 2016 ; Tables 1  and 2 ). While the type and duration of the antibiotic treatment (Mueller et al. 2015) Prenatal abx Prenatal 3 years' old Cohort study Variety of abx Increased asthma rates in children at risk (Lapin et al. 2015) Prenatal abx Prenatal 0-5 years' old Large cohort study Several types for non-respiratory infections.
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( Korpela et al. 2016a,b) Up to 24 months of abx exposure Abx, antibiotics may modulate the specific microbial alterations, it has been demonstrated that even brief antibiotic treatments can have long-term effects on microbiota composition (Lange et al. 2016; Isaac et al. 2017) . Such changes in microbiota are termed dysbiosis, a microbial imbalance that is correlated with impaired health. Dysbiosis has been associated with many disease states including autoimmune diseases, metabolic diseases, malnutrition and others. The microbiota has been shown to play roles in modulating the immune system, in hormone secretion and responses and in metabolism (Spor, Koren and Ley 2011; Neuman et al. 2015; Blaser 2016; Shamriz et al. 2016) . Therefore, alterations to microbiota compositions caused by antibiotics are likely to have additional health consequences, specifically associated with weight gain and metabolic imbalance, as well as susceptibility to diseases. Indeed, early childhood antibiotic exposure is associated with increased risk for excessive weight gain, asthma, allergies and autoimmune diseases, such as inflammatory bowel diseases (IBD) (Cho et al. 2012; Cox et al. 2014; Bokulich et al. 2016; Korpela et al. 2016a,b; Mahana et al. 2016; Turta and Rautava 2016) . As the microbiota have been shown in models of germ-free animals to play a role in development of brain structure, and potentially function, concerns have also been raised regarding possible effects of antibiotics in child brain development (Diamond et al. 2011; Diaz Heijtz et al. 2011) . The hygiene hypothesis proposes that exposure to environmental microorganisms and parasites is important for healthy development and maintenance of the immune system (Liu 2007) . With the increased hygiene levels in Western countries in recent decades, contact with microorganisms has significantly decreased, potentially diverting normal differentiation of immune cells and consequently raising rates of allergies, asthma and autoimmune disease (Liu 2007; Versini et al. 2015) . As antibiotics are a factor that reduces exposure to microorganisms and disrupts the body's natural microbiota, this hypothesis may help explain the observed effects of antibiotics on the immune system.
The infant and child microbiome
The infant microbiome differs from that of adults, and is rather dynamic and less diverse in children up to 2 years of age (Spor, Koren and Ley 2011) . These dynamics are consistent with the various encounters with microorganisms occurring in early post-natal life, when the infant acquires his initial microbiome. Distinct compositions are observed in the gut microbiota of infants due to variations in mode of delivery (vaginal vs. Cesarean section) and diet (breastfeeding vs. formula; DominguezBello et al. 2010; Bezirtzoglou, Tsiotsias and Welling 2011; NurielOhayon, Neuman and Koren 2016) .
Furthermore, when monitoring a single infant, significant shifts were seen in microbial compositions following change of diet (from milk to cereal and solid foods), and other environmental factors (Koenig et al. 2011) .
In preterm infants (gestational age <36 weeks), maintaining a healthy microbiome composition is of extreme importance, as the phylogenetic diversity is low to begin with, and severe dysbiosis can lead to necrotizing enterocolitis or late-onset sepsis (Dollings and Brown 2016) . The preterm infant's microbiome is characterized by reduced Bacteroidaceae abundance during the first months of life and by a higher initial abundance of Lactobacillaceae as compared to full term infants (Arboleya et al. 2015) . Additionally, the initial preterm microbial composition is highly influenced by communities colonizing the hospital 
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Abx, antibiotics setting, and is enriched in Staphylococcus epidermis, Klebsiella pneumoniae and Escherichia coli (Brooks et al. 2014) . This makes the premature infant microbiota richer in Proteobacteria and more vulnerable to instability and disease. Routine prophylactic antibiotic treatment is given to most preterm infants in an attempt to minimize infections, and possibly further leads to vulnerable microbiota. Therefore, the potential side effects on microbiome composition should be considered, if possible, when giving antibiotics at this stage. Since infancy is a crucial time for microbial establishment, it is necessary to evaluate the influence of antibiotics given quite liberally during this period. Antibiotic treatment given to both infants and toddlers has already been shown to strongly affect microbiome composition (Yassour et al. 2016) . Further studies are required to determine whether these are transient, or rather, long-term effects and to assess a potential window of time when interventions are most harmful. It is also important to test whether and how perinatal antibiotics influence the microbiota later in life.
Methods to study the effects of antibiotics on the microbiome
In an attempt to understand the effects of antibiotics on the microbiome, both human reports and experiments in animal models have been employed. Analysis of the human studies is especially complex as there may be a variety of reasons and medical indications for the antibiotic treatment, and thus, the treated population may initially differ from the untreated (healthy) controls. Therefore, large study groups are needed in order to distinguish the effects of the antibiotics from other confounding factors. Alternatively, animal studies in which healthy animals of the same genotype receiving similar diets are treated with antibiotics or left as untreated controls, may be able to indicate specific effects of antibiotics on microbiota, minimizing background 'noise.' However, mouse and human microbiota compositions and immunity are not identical, so these studies have limited relevance to human health. To this end, another technique was developed and relies on gnotobiotic mice-initially germ-free mice that receive fecal transplants from human subjects. This allows the human microbial compositions to be studied in a mouse model. Thus, while no method appears to be perfect for analyzing microbial effects, the combination of recent findings from the multiple studies performed using various methods is likely to provide revealing insights.
When specifically assessing effects of antibiotics on the microbiota in children, it is important to consider which ages are sampled, how the microbiome composition is assessed (16S rRNA gene sequencing, real-time PCR (RT-PCR) using specific primers or other methodologies), along with the type and dose of treatment. In most murine models assessed, antibiotics are given early in life at two stages: from the prenatal period (administered to the pregnant dams) up to weaning, and postweaning. Studies in humans include recording outcomes of antibiotics administered at prenatal stages, to infants and in childhood.
It is important to note that most studies in this field have been correlative, linking use of antibiotics with the various physiological outcomes. While many of the findings seem convincing, more research is needed to prove causality, and determine specific mechanisms of antibiotic-mediated effects.
Antibiotics have both short and long-term effects on the microbiome
Many recent studies have focused on deciphering short and long-term alterations of the microbiota following antibiotic treatment. While most studies report significant effects, there are some inconsistencies between studies, perhaps due to different dosages, route and length of administration, type of antibiotics and other environmental and genetic variables. In general, the most common effects of antibiotics on the gut microbiota are decreased phylogenetic diversity and richness, increased abundance of Proteobacteria including Enterobacteriaceae, leading to a pro-inflammatory state and enhanced bacterial expression of antibiotic resistance genes.
Most effects of antibiotics on microbiota composition persist for a period of weeks to several months, although some reports have found significant differences in microbial composition even 2 years after exposure (Jernberg et al. 2007) . Such microbiota changes may lead to long-term expression of antibiotic resistance, and physiological alterations associated, for example, with the function of the immune system or metabolism, lasting even years after the antibiotic exposure.
Normally, antibiotics are administered to eliminate pathogenic bacteria at times of bacterial infection. However, most types of antibiotics are not entirely specific, and therefore also eliminate a broad range gut microbial inhabitants that are not pathogenic, and are often crucial for health. This explains the decrease in α diversity (richness) after antibiotic treatment seen in several studies (Sato, Yoshida and Tuboi 1989; Tanaka et al. 2009; Bokulich et al. 2016) . When diversity is low, normal microbial homeostasis is disrupted and the microbiota is more susceptible to intrusions and colonization of pathogens. Accordingly, the decreased diversity due to antibiotics is generally disadvantageous. Similarly, decreased numbers of microbial species are a common characteristic of disease states and are a general indication of a 'weaker' microbiome (Mosca, Leclerc and Hugot 2016) . Therefore, therapies to regain healthy microbial richness, such as prebiotics and probiotics, may be useful after use of antibiotics.
Of the few studies performed on healthy adult volunteers, one study tested the effects of clindamycin treatment for 1 week on microbial composition, and found significant differences even 2 years after treatment. These included loss of diversity, alterations in specific taxa abundance and upregulation of antibiotic resistance genes (Jernberg et al. 2007) . While Bacteroides abundance was decreased following antibiotic exposure, as could be predicted based on clindamycin's target range, there was an increase in abundance of highly resistant Bacteroides spp. clones, which persisted up to 2 years (Lofmark et al. 2006) . While in the case of Bacteroides this may not be deleterious on its own, it may raise concerns regarding spreading resistance horizontally to other species. However, answering this requires larger cohorts and additional studies.
Most of the antibiotics used in microbiome studies are broad spectrum antibiotics targeting a wide range of pathogens. These include penicillins, macrolides and vancomycin. Additional types of antibiotics used in studies include metronidazole and streptomycin. Importantly, not all antibiotics have similar effects on the microbiota. As different types of antibiotics have distinct modes of action, they may ablate specific sub-populations of the microbiota. An example of this is seen when comparing the effects of two common antibiotic treatments for Clostridium difficile (C. difficile), metronidazole and oral vancomycin in mice; vancomycin was shown to more markedly disrupt the microbiota, leading to decreased resistance to C. difficile infection in the long term, and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae and E. coli (Lewis et al. 2015) . Indeed, one of the most worrisome phenomena attributed to chronic use of antibiotics is increased abundance of opportunistic pathogens in the gut, especially C. difficile, displacing the healthy microbiota populations and leading to acute dysbiosis (Bien, Palagani and Bozko 2013) . In some cases, this may further cause predisposition to infection by pathogens such as Salmonella or Campylobacter spp. (McDonald 2017) . In addition, C. difficile infection can itself eventually lead to antibiotic-associated diarrhea and colitis, manifesting long-term disease. Another example of diverse effects of different antibiotics on the microbiota can be found in a murine study comparing effects of vancomycin vs. streptomycin, where only vancomycin had apparent effects on the microbial composition (Russell et al. 2012) . Altogether, data suggest that different antibiotics disrupt the microbiota in different ways. Perhaps the effects of each specific antibiotic on the microbiota should be taken into account by physicians when deciding which antibiotic to prescribe.
Antibiotics affect the infant and child microbiome
While there are similarities between the compositional effects of antibiotics on adult and infant microbiota, there are also some differences due to the distinct characteristics of the infant microbiota. The general trend of decreased microbial diversity due to antibiotic treatment is seen in children as well as in adults (Yassour et al. 2016) . A recent study of 142 Finnish children aged 2-7 years demonstrated that macrolides alter the microbiota composition and its potential metabolic functions (Korpela et al. 2016a,b) . More specifically, use of macrolides decreased Actinobacteria abundance, including the genus Bifidobacteria, while increasing the abundance of members of the Bacteroidetes and Proteobacteria phyla (including Enterobacteriaceae), compared to children not receiving antibiotics. These microbial alterations lead to significantly lower expression levels of microbial bile-salt hydrolases, which play an important role in host metabolism and weight gain restraint (Korpela et al. 2016a,b) . Similarly, in a study in which human neonates received broad spectrum antibiotics for the first 4 days of life, arrested growth of Bifidobacterium was seen up to 1 month, overgrowth of Enterococci was observed since the first day and increased growth of Enterobacteriaceae was seen even 2 months after cessation of treatment (Tanaka et al. 2009 ). In contrast, penicillin does not have the same effects on children's microbiome composition, as there are no significant taxonomical differences between untreated and penicillin-treated infants (Korpela et al. 2016a,b) .
Several studies in young mice reported direct effects on microbiota composition as well. When sub-therapeutic levels of antibiotics were administered to young mice from the time of weaning, the gut microbial populations from mice receiving antibiotics were more similar to one another than to those of control mice (Cho et al. 2012) . Specifically, the ratio of Firmicutes to Bacteroides as well as representation of Lachnospiraceae was significantly elevated following antibiotic treatment. Administration of low-dose penicillin (LDP) to mice in late pregnancy and in early postnatal life resulted in changes in the gut microbiota lasting weeks after antibiotic exposure, including lower overall diversity, a dramatic increase in Proteobacteria abundance (from 0.5 to 80%), an increase in the Firmicutes/Bacteroidetes ratio and a decrease in Cyanobacteria and Actinobacteria abundance. A similar side effect was found after cefoperazone treatment; mice had altered bacterial communities even 6 weeks after cessation of treatment (Antonopoulos et al. 2009 ).
Given its low species diversity, the preterm infant microbiome is especially sensitive to antibiotics. A 5-7 day course of antibiotic treatment (ampicillin and gentamycin) in premature infants during first week of life increased the relative abundance of Enterobacter and lowered bacterial diversity in the second and third weeks of the infants' life (Greenwood et al. 2014) . It was shown that antibiotics, including meropenem, ticarcillin-clavulanate and cefotaxime, given to preterm infants greatly reduce species richness and increase expression of antibiotic resistance genes (Gibson et al. 2016 ). However, gentamicin and vancomycin had variable effects and did not clearly lower species richness.
In summary, both the short and long-term effects of antibiotics on the infant and child's microbiota are evident. Some antibiotics cause more dramatic changes than others, and some infants such as preterm infants, are probably more sensitive to the effects of antibiotics on the microbiome.
Perinatal antibiotic exposure modulates the infant microbiota
Even perinatal antibiotic exposure is sufficient to modulate the infant microbiota (Kuperman and Koren 2016) . When mothers received intrapartum antibiotic prophylaxis (IAP) before delivery, their offspring had a unique microbiome composition, which persisted up to 3 months of age, and included overrepresentation of Enterococcus and Clostridium at the expense of Bacteroides and Parabacteroides genera (Azad et al. 2016) . Similarly, perinatal antibiotics, including an IAP regimen, alter the premature infant gut microbiota composition, raising levels of Enterobacteriaceae species (Arboleya et al. 2015) . Several studies in murine models have also demonstrated that antibiotic exposure from the perinatal stage and up to weaning has a marked effect on the gut microbiota (Russell et al. 2012; Cox et al. 2014) . In mice receiving LDP perinatally and through weaning, a distinct gut microbiota composition was observed at 4 weeks of age including reduced levels of Lactobacillus, Candidatus Arthromitus (segmented filamentous bacteria, SFB) and Allobaculum abundance (Cox et al. 2014) . It is yet to be determined whether the perinatal antibiotic effects are a result of disruption of the maternal microbiota (thereby transferring an altered microbiota to the offspring), or an indirect effect on the offspring (e.g. by affecting the immune system). Nonetheless, these findings highlight the effects of maternal antibiotics during late pregnancy on the microbiota of the progeny.
Childhood antibiotics modulate the immune system
The effect of antibiotics on the natural microbial communities may consequently modulate the immune function and promote illness associated with dysfunctional immune system. This might be especially true in the case of antibiotics administered in early childhood, a period during which the immune system is developing in coordination with the nascent microbial colonization. Indeed, use of antibiotics during childhood has been correlated with increased risk of allergy, asthma, various infections and IBD (Langdon, Crook and Dantas 2016; Leclercq et al. 2017) . Allergies are extremely common chronic diseases in which the T-helper 2 (Th2) arm of the adaptive immune response is hyperactivated. It has been postulated that microbial dysbiosis can affect the Th2 response and may lead to increased susceptibility to allergies (Fujimura and Lynch 2015) . The microbiota has a crucial role in generating a balanced immune phenotype that involves maturation of the Th1 and Th17 cells response and the development of T regulatory (Treg) cells, which suppress the Th2-phenotype (Alexander, Targan and Elson 2014; Faith et al. 2014; Ohnmacht et al. 2015; Sefik et al. 2015; Tan et al. 2016; Zhang, Zhivaki and Lo-Man 2017) . For example, certain Clostridia species are associated with increased numbers of Treg cells in the mouse colon (Atarashi et al. 2011) , while SFB promote the development of Th17 cells (Wu et al. 2010) . The immune maturation process in the respiratory mucosa is also modulated during initial microbial colonization (Fujimura and Lynch 2015) . Programmed death ligand (PD-L1) is necessary to induce the development of Treg cells in the lung, whose presence is inversely related to the allergic response to the house dust mite. Within the first 2 weeks of life, in parallel with changes in the bacterial profile, PD-L1 expression peaks in the murine lungs of normal mice but not in germ-free mice (Gollwitzer et al. 2014 ). The bacteria possess a variety of mechanisms to modulate the immune system, such as generation of metabolic products, including short chain fatty acids (SCFA), from dietary substrates, which can promote Treg cells (Arpaia et al. 2013; Furusawa et al. 2013; Smith et al. 2013; Chang et al. 2014) .
The correlation between asthma and antibiotic exposure during the perinatal period or infancy was also investigated (Kummeling et al. 2007; Russell et al. 2013; Stensballe et al. 2013; Ortqvist et al. 2014; Lapin et al. 2015; Hirsch et al. 2017) . A cohort study examined a correlation between infant exposure to antibiotics during the first 6 months of life, and eczema, wheeze and allergic sensitization at 2 years, and demonstrated that direct exposure to antibiotics increased the risk for recurrent and prolonged wheeze, though not allergic sensitization or eczema (Kummeling et al. 2007) . In another large cohort study of children born to mothers with asthma, increased risk of asthma was associated with maternal antibiotic use during the third trimester of pregnancy (Stensballe et al. 2013) . Correlations between macrolide treatment in children and increased risk for asthma (Korpela et al. 2016a,b) , and a correlation between exposure to three or more courses of antibiotics up to 7 years of age and greater odds of food allergies, including allergies to milk (Hirsch et al. 2017) were also demonstrated. Although, in one cohort analysis, antibiotics used to treat respiratory infections in childhood were associated with increased risk of asthma, but the excess risk was decreased when siblings were analyzed (Ortqvist et al. 2014) . This study emphasizes the necessity to assess additional associations between the exposure to antibiotics in early life and subsequent childhood allergy such as genetics and environmental factors.
Concurrent with the studies in children showing correlations between early life antibiotic treatment and asthma, exposure of prenatal and neonatal mice, but not adults, to antibiotics resulted in exacerbated asthma following intranasal challenge with ovalbumin (Russell et al. 2012) . Moreover, a critical period was defined between birth and 3 weeks of age, during which an antibiotic-driven shift in microbiota can alter the immune response and increase susceptibility to allergy. These effects were observed when mice were exposed to vancomycin but not streptomycin. While trying to decipher the underlying mechanisms, it was found that vancomycin may lead to elevation of serum IgE and reduced regulatory T cell populations (Russell et al. 2013) . Notably, in contrast to allergic responses, neonatal exposure to streptomycin but not vancomycin dramatically enhanced subsequent development of the Th1/Th17-mediated lung disease, hypersensitivity pneumonitis (Russell et al. 2015) . This suggests that the distinct effects of individual antibiotics on microbiota composition early in life can differentially direct immune development. Indeed, exposure of mice to single antibiotics of varying spectra between days 10 and 20 of life had a range of effects from abrogation of oral tolerance to the spontaneous development of Th2 responses (Gustafsson, McDonald and Newberry 2016) .
In terms of autoimmune disease, a cohort study found increased risk for IBD in children receiving antibiotics (Hviid, Svanstrom and Frisch 2011) . This risk factor was especially high for Crohn's disease (CD) and was strongest in the first 3 months following antibiotic administration, as well as in children receiving ≥7 courses of antibiotics (Hviid, Svanstrom and Frisch 2011) . Mechanistically, a study in mice demonstrated that antibiotic treatment during gestation and early life induced a more rapid onset of IBD due to enhanced effector function of CD4 + T cells (Scheer et al. 2017) . They further showed that antibiotic treatment in early life resulted in a stress response, with high levels of corticosterone, which influence CD4 + T cell function.
In summary, the combined findings in several large birth cohort studies as well as mouse studies present a strong link between childhood antibiotics, altered microbial composition and an aberrant immune response leading to increased risk for allergies and IBD. Data suggest that early in life, the immune system is skewed toward the Th2 phenotype, which facilitates safer microbial colonization in a way that avoids excessive inflammation or tissue damage (Fujimura and Lynch 2015) . In turn, the colonizing microbiota divert the immune response to its mature balanced phenotype associated with the Th1/Th17/Treg responses. When the dialog between the microbiota and the immune system is destabilized, for example as a consequence of antibiotic usage, either the maintenance of the infantile phenotype increases the risk of allergy, or alternatively, abrogation of the delicate tolerance by unregulated inflammatory processes increases the risk for autoimmune diseases, especially those involving primary sites of the microbiota, such as IBD.
Childhood antibiotics affect weight gain
Several studies have investigated a link between childhood antibiotics and weight gain (Turta and Rautava 2016) . This may not be surprising, since antibiotics have been used in the agricultural industry as a growth promoter for over 60 years, even though the precise mechanisms underlying this effect are as yet unknown (Cromwell 2002; Butaye, Devriese and Haesebrouck 2003) . In mice, 7 weeks after exposure to sub-therapeutic doses of various antibiotics, the total fat mass was significantly higher in the treated mice compared to the controls (Cho et al. 2012) . Moreover, while mice treated with LDP from the prenatal period until weaning exhibited altered microbiota composition for only 1 month, their body mass and fat content were higher even in adulthood, indicating an extended metabolic effect of shortterm antibiotic treatment (Cho et al. 2012; Cox et al. 2014) . Interestingly, there were some differences between effects in males and females following antibiotic administration. Whereas an increase in fat mass as well as a decrease in bone area and mineral content was observed specifically in males, in females there was a significant rise in bone mineral density following treatment. The effects on total and fat mass were even more severe when antibiotics were given perinatally and up to weaning, as opposed to post-weaning. The increased body mass phenotype is transferrable to germ-free mice by microbiota from LDPexposed mice, demonstrating that the altered microbial compositions caused by the antibiotics play a causal metabolic role (Cox et al. 2014) . In yet another study, increased adiposity, insulin resistance and liver disease related to high-fat diet were observed in mice receiving long-term LDP treatment from 2 weeks of age (Mahana et al. 2016) . These changes correlated with microbial alterations. Finally, a mouse study attempting to mimic childhood antibiotics by pulsed antibiotic treatments starting from weaning showed a strong correlation between varying antibiotic regimes and body mass, bone growth and slower microbiota adaptation to changes in diet (Nobel et al. 2015) .
Recently, a study in pre-school children found that use of macrolides in early life correlates with increased weight gain (Korpela et al. 2016a,b) . This weight gain was also associated with microbial taxonomical changes including in the abundance of Clostridium, Akkermansia and Enterococcus. Even exposure of the fetus to antibiotics, administered to the mother during pregnancy, may result in long-term effects on growth. For instance, it was demonstrated that when pregnant women received antibiotics during the second and third trimester of pregnancy, their offspring had an 84% increased risk for childhood obesity, up to 7 years of age (Mueller et al. 2015) .
The mechanisms underlying the causative role of the microbiota composition on the host metabolic function are not clear yet, but several pieces of evidence link the initial microbiota alterations due to antibiotic treatments with long-lasting metabolic effects: early life antibiotic administration in mice was associated with changes in microbial copies of key genes involved in the metabolism of carbohydrates to SCFAs, and increased colonic SCFA levels (Cho et al. 2012 ). Due to this overproduction in early life, the ecosystem might not be able to recover (Cho et al. 2012) . Also, early life LDP, in a microbial dependent manner, reduced the expression of transcription factors and cytokines important for Th1 and Th17 cell differentiation and function in the intestinal mucosa (Cox et al. 2014) . This might be the result of the significant reduction in the abundance of the bacteria Lactobacillus, Allobaculum, Rikenellaceae and C. Arthromitus in response to LDP, all with known effects on the immune functions (Cho et al. 2012; Cox et al. 2014) . It is possible therefore that altering intestinal immune programming has a long-lasting effect on the immune resistance, and inflammatory conditions are known to be associated with metabolic syndromes. Further understanding the mechanisms underlying the effects of different type of antibiotics on metabolism is crucial to be able to develop counter interventions.
Antibiotics and neurodevelopment
There is now strong evidence, in humans and rodents, supporting the influence of the gut microbiota on central nervous system development, brain function, and mood/behavior (Forsythe, Kunze and Bienenstock 2016) . Studies in germ-free animals demonstrate that the absence of intestinal bacteria results in changes in brain neurochemistry (Neufeld et al. 2011) , decreased anxiety and altered social behaviors (Neufeld et al. 2011; Desbonnet et al. 2014) , hyperactivity of the hypothalamuspituitary-adrenal axis (Sudo et al. 2004 ) and an immature phenotype in microglia (Erny et al. 2015) . While many of these disruptions in central nervous system (CNS) function can be replicated in animal models exposed to high-dose antibiotic cocktails (Forsythe, Kunze and Bienenstock 2016) , there have been few studies examining the potential effects of clinical antibiotic use on neurocognitive outcomes. However, a recent study (Slykerman et al. 2017) identified an association between antibiotic treatment in the first year of life and inferior cognitive, behavioral and emotional outcomes throughout childhood.
Examining 526 children, investigators demonstrated greater behavioral difficulties at 3.5 years and 7 years, and a greater number of ADHD and depressive symptoms at the age of 11 in those exposed to antibiotics. Furthermore, a causal relationship between early life antibiotic treatment and changes in neurodevelopment has been suggested in a mouse model demonstrating that LDP in late pregnancy, and the early postnatal period in mice lead to increased anxiety-like and impaired social behaviors, together with increased aggression in early adulthood (Leclercq et al. 2017) . These behavioral changes had neural correlates, with increased expression of cytokines and arginine vasopressin receptor 1B in the frontal cortex, as well as modification of blood-brain barrier integrity (Leclercq et al. 2017) . Arginine vasopressin receptor 1B has previously been associated with aggressive behavior (Wersinger et al. 2002) . Together, these studies raise concerns and identify the need for further investigations regarding the side effects of early life antibiotic treatment on the development of neurodevelopmental and mood disorders.
Antibiotic resistance
The increasing number of antibiotic prescriptions is considered to be the main factors causing the antibiotic resistance crisis (Ventola 2015) . Various observations reveal that exposure to antibiotics leads to elevated and long-term expression of microbial antibiotic resistance genes, as well as increased abundance of resistant bacterial strains (Langdon, Crook and Dantas 2016) . Selective pressure as well as the innate immune alterations triggered by antibiotic exposure may be exploited by antibioticresistant bacterial pathogens, enabling them to thrive following antibiotic treatment (Brandl et al. 2008) .
The expression of antibiotic resistance genes and species has been termed the resistome. Characterization of the gut resistome of 22 healthy infants and children aged 0-19 years demonstrated that infants and children harbored genes conferring resistance to 14 out of the 18 antibiotics tested (Moore et al. 2013) . The healthy childhood resistome was highly diverse, and the resistance genes appear very early in life (Moore et al. 2013) . Moreover, even healthy preterm infants have been found to harbor a diverse resistome (Rose et al. 2017) .
A longitudinal study found that children receiving antibiotics in the first 3 years of life contained microbiota expressing higher levels of antibiotic resistance genes as compared to controls, with a peak in their abundance after antibiotic treatment, followed by a sharp decline (Yassour et al. 2016) . However, antibiotic resistance genes on microbial mobile elements tended to persist longer after antibiotic withdrawal (Yassour et al. 2016) . This study also found that some children harbored antibiotic resistance genes prior to any antibiotic treatment. Similarly, in a study testing microbiota in dental plaques in children, although previous amoxicillin usage increased the numbers and proportions of resistant bacteria, resistance to amoxicillin was found both in children receiving amoxicillin during the previous 3 months and in those not exposed to antibiotics (Ready et al. 2004) . Altogether these studies demonstrate that a side effect of antibiotic treatment is the increase in abundance of antibiotic resistance genes and consequently increase their potential for horizontal spreading in the healthy community.
Effects of probiotic and prebiotic treatment on children's microbiome and overall health
With the evident effects of antibiotics on the microbiota, it has been suggested that probiotics and prebiotics may be able to alleviate the symptoms and restore the microbial balance. Probiotics are supplements comprised of live bacteria that are considered beneficial, usually including Lactobacillus, Lactococcus or Bifidobacterium. To this end, many medical practitioners recommend probiotics following antibiotic treatment. While some studies with probiotics yielded insignificant results, other studies suggested a clear health benefit following antibiotics. Different microbial compositions were found in mice receiving probiotics after antibiotic treatment, compared with mice receiving antibiotic treatment alone (Grazul, Kanda and Gondek 2016) . Long-term L. rhamnosus GG supplementation was found to influence the composition of the intestinal microbiota in children as well, causing an increase in the abundance of Prevotella, Lactococcus and Ruminococcus, and a decrease in Escherichia (Korpela et al. 2016a,b) . Additionally, probiotics were suggested to alleviate some of the antibiotic-associated side effects such as diarrhea (Kligler, Hanaway and Cohrssen 2007) and revert the increased risk for atopic diseases following antibiotics (del Giudice et al. 2012) . It has even been speculated that probiotics in combination with antibiotics may reduce antibiotic resistance, although this requires further investigation (Ouwehand et al. 2016) .
Prebiotics, such as short chain fructo-oligosaccharides and galacto-oligosaccharides, are dietary factors that enhance the growth of bacteria such as Bifidobacterium and Lactobacillus, and are therefore suggested to help normalize the microbiota following antibiotics. Prebiotics have been shown to shift microbial populations in neonates as well as children (Nicolucci et al. 2017; Sohn and Underwood 2017) . Prebiotics administered in milk formula to infants after antibiotic administration were found to increase fecal Bifidobacteria as compared to infants receiving only antibiotics (Brunser et al. 2006) . Additionally, bacterial intestinal overgrowth syndrome (SIBO) symptoms were found to be improved when treated with antibiotics together with prebiotics or probiotics (Rosania et al. 2013) . Despite the need for more research in order to fit the precise pre and probiotic treatments, it appears that these may be beneficial in children following antibiotics.
CONCLUSION
While antibiotics remain an essential medical treatment saving millions of lives, it is important to highlight the detrimental long-lasting effects associated with their use. It seems apparent that antibiotics in general, and specifically those administered during early childhood, have major effects on the microbiota composition. While there are discrepancies between different types and dosage of antibiotics, there are also some common effects. The most common effects include a dramatic decrease in overall species diversity, a significant increase in the abundance of Proteobacteria and higher Firmicutes/Bacteroidetes ratios. Many of these alterations were also seen in mouse studies, in which diet and host genotype were monitored. Typically, these microbial alterations persist weeks to months after antibiotic exposure. Studies have highlighted different effects of different antibiotics on the microbiota composition or severity of dysbiosis, and therefore the specific antibiotic prescribed requires careful consideration. Antibiotics, as well as the related altered microbial profiles, have been correlated with metabolic and immune deficiencies, leading to increased risk for weight gain, allergies and IBD. While the microbial effects are relatively short-lasting, effects of perinatal or antibiotic exposure at infancy may have physiological influences lasting even years, and potentially into adulthood. These findings define early life as an especially sensitive timeframe for antibiotic use. Therefore, antibiotics administered during late pregnancy and in infancy should be critically and carefully assessed while keeping in mind that appropriate antibiotic treatment save lives every day.
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